Ophidion in a few facts
News and Highlights
September, 2024
- Ophidion will provide an update on our technology at the 4th RNA leader in the US conference, San Diego, September 4th-5th
- Intravenously delivery of a peptide:ASO6 complex halted disease progression in two chronic studies in humanized Huntington’s mice
- Intravenously delivery of a peptide:ASO6 complex showed significant knock-down in Huntington’s protein in various brain regions in non-human primates
- Phase 1b/2a in Huntington’s patients is expected to start shortly.
- Ophidion will provide an update on our technology at the 4th RNA leader in the US conference, San Diego, September 4th-5th
January, 2024
- Ophidion conducted its 1st non-human primate study that delivers proof-of-concept data.
- Intravenously delivering of a peptide:ASO6 complex showed significant knock-down in Huntington’s protein in various brain regions of wild-type non-human primates.
- Ophidion conducted its 1st non-human primate study that delivers proof-of-concept data.
January, 2023
- Ophidion conducted two long-term chronic studies in a transgenic Huntington mouse model that established Huntington rodent proof-of-concept.
- Intravenously delivering of an OCCT:ASO6 complex significantly suppressed HTT gene expression and protein content in multiple brain regions after three months and six months of chronic therapy.
- This Huntington proof of concept included an inverse correlation between the reduction in soluble mutant HTT protein levels in brain regions and return of wild-type behavior.
- Ophidion conducted two long-term chronic studies in a transgenic Huntington mouse model that established Huntington rodent proof-of-concept.
June, 2022
- Ophidion provided an update on our technology at the RNA THERAPEUTICS & DELIVERY conference, Boston, June 13th -14th
- Intravenously delivering a peptide:siRNA complex significantly reduced Huntington mRNA in a mouse model of Huntington Disease.
- Ophidion provided an update on our technology at the RNA THERAPEUTICS & DELIVERY conference, Boston, June 13th -14th
December, 2019
- Ophidion, Inc. closes Series Seed round for a total of $1.7M led by Robin Hood Ventures: Philadelphia-based angel investor group Robin Hood Ventures (RHV) announced an initial investment in Ophidion Inc., a Pennsylvania-based private biotechnology company. Ophidion Inc has a platform technology that acts as a Trojan horse to shuttle various cargoes across the BBB following intravenous administration.
- The company is currently focused on developing a pipeline to deliver gene silencing therapies to treat neurodegenerative diseases, including diseases of Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease).
- This seed series will be used to advance the Huntington’s program through preclinical proof of concept, which would de-risk the entire platform as well as position the Huntington’s program to start the IND-enabling studies. In addition to Robin Hood Ventures, four other groups invested in Ophidion Inc. during this seed round. Those groups were: Ben Franklin Technology Partners, Delaware Crossing Investor Group, Viva Incubator Investment Management Limited, and Gaingels.
- Ophidion, Inc. closes Series Seed round for a total of $1.7M led by Robin Hood Ventures: Philadelphia-based angel investor group Robin Hood Ventures (RHV) announced an initial investment in Ophidion Inc., a Pennsylvania-based private biotechnology company. Ophidion Inc has a platform technology that acts as a Trojan horse to shuttle various cargoes across the BBB following intravenous administration.
June, 2018
- Ophidion, Inc., a biotechnology company advancing innovative gene silencing therapeutics for the treatment of brain diseases, has hired Yacoub Habib, Ph.D./MBA as its chief executive officer.
May, 2018
- Ophidion, Inc., a biotechnology company advancing innovative gene silencing therapeutics for the treatment of brain diseases, announced today that it is a recipient of the latest investment cycle of the Ben Franklin Technology Partners of Northeastern Pennsylvania (BFTP/NEP) network regional economic development investment program.
- The BFTP/NEP investment was for $100,000 to support a definitive preclinical study to optimize the delivery of central nervous system therapeutics to targeted sites in the brain. Ophidion is leveraging its proprietary BBB transport technology to advance a systemically delivered gene-silencing siRNA product for the treatment of Huntington’s disease, a fatal neurodegenerative disease with no current cure.
- The Ben Franklin Technology Partners’ Board of Directors made investments totaling $695,000 in this cycle in support of regional early-stage companies. These investments are provided in the form of loans with warrants. BFTP/NEP’s goal is to help lead northeastern Pennsylvania to a better economic future by building partnerships that develop and apply technology for competitive advantage.
Contact Us
-
Yacoub Habib, CEO.
Tel: (973)-687-2165
Email: [email protected] -
Pasadena Bioscience Collaborative
2265 E Foothill Blvd
Pasadena, CA 91107